What we know — and don’t know — about Merck’s new Covid-19 pill

Posted on AllSides October 11th, 2021
From The Center
Mel Evans/AP

The announcement that a pill from Merck and partner Ridgeback Biotherapeutics kept Covid patients out of the hospital made headlines and moved stocks late last week. But as is so often true when data are released by press release, there are still many questions left unanswered.

Doctors are excited about the medicine, molnupiravir, because a regimen of pills, even one that involves taking several pills twice a day for five days, should be far easier to deliver to patients than current antiviral Covid-19 treatments, which must be given intravenously. But it’s still...

Read full story

STAT

AllSides Media Bias Rating: Center
AllSides Media Bias Rating: Center
106710/84317
See full bias rating for STAT
Learn about media bias
https://www.statnews.com/2021/10/04/what-we-know-and-dont-know-about-mercks-new-covid-19-pill/

More News about Coronavirus from the Left, Center and Right

From the Left

From the Center

From the Right